MUC1 Decoy Peptides Block Pseudomonas Aeruginosa Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pseudomonas aeruginosa infections are challenging to treat due to antibiotic resistance, necessitating alternative strategies for preventing and treating these infections, particularly in immunocompromised patients and those with cystic fibrosis, where the bacteria colonize and infect the respiratory tract.
Innovation Solution
The use of MUC1 decoy peptides, derived from the extracellular domain of the mucin-1 protein, which competitively block P. aeruginosa adhesion to airway epithelial cells by mimicking the natural binding site, and their administration in pharmaceutical formulations to prevent or treat infections, potentially in conjunction with antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat P. aeruginosa infections, then bacterial growth is inhibited, but antibiotic resistance develops rendering treatment ineffective
Solution Approach 1:
The patent introduces MUC1 decoy peptides as intermediary molecules that mediate between the bacterial flagellin and the host cell receptors. These peptides bind to flagellin with high affinity, acting as soluble decoys that intercept bacterial adhesion attempts before they can reach cellular MUC1 receptors, thereby preventing infection without relying on antibiotics and avoiding resistance development
Solution Approach 2:
The invention creates simplified copies of the natural MUC1 ectodomain binding interface in the form of synthetic peptides. These peptide copies replicate the key binding features of full-length MUC1 but in a soluble, stable format that can circulate and bind flagellin, providing protective decoy function without the complexity and instability of the full protein
2Reliability
If MUC1 decoy peptides are administered to block bacterial adhesion, then infection is prevented, but new therapeutic approach requires validation
Solution Approach 1:
The patent employs multiple feedback mechanisms to validate the decoy peptide mechanism: (1) binding assays that measure peptide-flagellin interaction strength, (2) adhesion inhibition assays that quantify reduction in bacterial attachment to epithelial cells, and (3) in vivo infection models that demonstrate protection against pneumonia. These layered feedback approaches provide comprehensive validation of the therapeutic mechanism
Solution Approach 2:
The invention replaces complex mechanical and structural validation requirements with simplified biochemical and cellular assays. Instead of requiring detailed structural biology to prove mechanism, the patent uses functional readouts such as binding affinity measurements (Kd values), adhesion percentage reductions, and colony-forming unit counts that directly demonstrate therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MUC1 decoy peptides effectively inhibit P. aeruginosa adhesion and invasion, offering a novel approach to managing resistant infections by leveraging the host's natural binding mechanisms, potentially enhancing treatment outcomes and reducing antibiotic reliance.
Implementation Method 1
a free form of MUC1-ED has been found to competitively block P. aeruginosa adhesion to cell-associated MUC1-ED
Data Source
AI summary
Pseudomonas aeruginosa flagellin protein recruits the mammalian host sialidase enzyme neuraminidase-1 (NEU1) to remove sialic acid residues from the extracellular domain of the mammalian cell-surface protein MUC1 (MUC1-ED), thereby exposing a cryptic binding site on the MUC1-ED protein backbone for flagellin binding. NEU1-driven MUC1-ED desialylation rapidly increases P. aeruginosa adhesion to the airway epithelium. MUC1-ED desialylation also increases MUC1-ED cleavage and shedding from the cell surface, where desialylated, shed MUC1-ED competitively blocks P. aeruginosa adhesion to cell-associated MUC1-ED. Presented herein are data showing that exogenously-administered, deglycosylated MUC1-ED peptides reduced adhesion of P. aeruginosa to airway epithelial cells. Also presented are data showing that administration of P. aeruginosa to mice in combination with deglycosylated MUC1-ED decreased P. aeruginosa recovered from the lungs at 48 hr and 72 hr post-infection. Such findings are extended to the methods of treatment and prevention of bacterial infections defined herein.